OakChart

Entrada Therapeutics Inc

TRDAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

5.44+0.19 (3.62%)
2026-11-11 22:49 CET
Market cap
205.54 USD m
Revenue, TTM
3.98 USD m
Net income, TTM
-161.39 USD m
Free cash flow, TTM
-136.33 USD m
EPS diluted, TTM
-3.84
P/E
-
Compare

Price

TRDA against its 20, 50 and 200-day averages
2050200beatmiss
5.007.5010.0012.50723K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TRDAclose 5.4420-day 4.7750-day 5.68200-day 8.525.4452w low

66.9% under the 52-week high of 16.45 on 6 May 2026. 52-week low 4.11 on 14 Oct 2026. Last 15 sessions, 29.0% high to low

Volume 2.18× normal · the line is the 50-bar volume average

Profile

TRDA
52-week range, 11% of the way up
4.1116.45

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which provides of a class of medicines that engages in intracellular targets. Its Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The company was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

IndexRUT
Employees152
IPOOct 29, 2021
Beta-0.18
ATR, 14d0.49
Rel volume2.18
Short float11.68%
Insider own38.60%
Inst own53.75%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap212.98M
Enterprise Value67.28M
Income-161.39M
Sales3.98M
Book/sh5.07
Cash/sh4.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees152
IPOOct 29, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S53.51
P/B1.07
P/C1.10
P/FCF-
EV/EBITDA-
EV/Sales16.90
Quick Ratio7.85
Current Ratio7.85
Debt/Eq0.24
LT Debt/Eq0.22
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.84
EPS next Y-3.54
EPS next Q-0.97
EPS this Y-11.41%
EPS next Y8.49%
EPS next 5Y2.15%
EPS past 3/5Y-4.74% -32.56%
Sales past 3/5Y- -
EPS Y/Y TTM-53.55%
Sales Y/Y TTM-93.54%
EPS Q/Q11.88%
Sales Q/Q-43.93%
EarningsNov 05 BMO
EPS/Sales Surpr.7.25% -60.58%

Ownership

Insider Own38.60%
Insider Trans-8.69%
Inst Own53.75%
Inst Trans0.38%
ROA-47.48%
ROE-59.88%
ROIC-66.96%
Gross Margin19.76%
Oper. Margin-4303.82%
Profit Margin-4057.98%
SMA2014.05%
SMA50-4.24%
SMA200-36.17%
Trades-

Technical

Shs Outstand39.15M
Shs Float24.04M
Short Float11.68%
Short Ratio8.03
Short Interest2.81M
52W High16.45 -66.93%
52W Low4.11 32.39%
Volatility10.69% 11.32%
ATR (14)0.49
RSI (14)54.14
Beta-0.18
Rel Volume2.18
Avg Volume349.55K
Volume760,700

Performance

Perf Week7.51%
Perf Month11.93%
Perf Quarter-26.98%
Perf Half Y-25.68%
Perf YTD-47.08%
Perf Year-29.35%
Perf 3Y-67.29%
Perf 5Y-83.28%
Perf 10Y-
Recom1.25
Target Price18.75
Prev Close5.25
Price5.44
Change %3.62%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 08, 2026DowngradeHH.C. WainwrightBuy → Neutral
Apr 01, 2026InitiatedCCantor FitzgeraldOverweight
Feb 11, 2026InitiatedGGuggenheimBuy$20+267.6%
Jan 28, 2026InitiatedOOppenheimerOutperform$21+286.0%
Dec 06, 2024InitiatedRROTH MKMBuy$29+433.1%
Jan 05, 2024InitiatedOOppenheimerOutperform$22+304.4%
Apr 03, 2023InitiatedHH.C. WainwrightBuy$25+359.6%

Peers

Mkt cap
TickerCompanyMkt cap
DYNDyne Therapeutics Inc3.37B
PEPGPepGen Inc364.31M
SRPTSarepta Therapeutics Inc1.79B
WVEWave Life Sciences Inc674.52M
SLDBSolid Biosciences Inc848.24M
CAPRCapricor Therapeutics Inc652.32M
EWTXEdgewise Therapeutics Inc5.21B
IONSIonis Pharmaceuticals Inc4.72B
ARWRArrowhead Pharmaceuticals Inc6.97B
PRQRProQR Therapeutics N.V177.81M

Insider trading

latest 14 of 57
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MPM BIOVENTURES 2018, L.P.10% OwnerSep 08 '26Sale7.41192,5001,426,4253,913,952Sep 09 07:24 PM
MPM BIOVENTURES 2018, L.P.10% OwnerSep 04 '26Sale7.1138,500273,7354,106,452Sep 09 07:24 PM
MPM BIOVENTURES 2018, L.P.10% OwnerSep 09 '26Sale7.1328,837205,6083,885,115Sep 09 07:24 PM
MPM BioVentures 2014, L.P.10% OwnerSep 08 '26Sale7.41192,5001,426,4253,913,952Sep 09 07:23 PM
MPM BioVentures 2014, L.P.10% OwnerSep 04 '26Sale7.1138,500273,7354,106,452Sep 09 07:23 PM
MPM BioVentures 2014, L.P.10% OwnerSep 09 '26Sale7.1328,837205,6083,885,115Sep 09 07:23 PM
MPM BIOVENTURES 2018, L.P.10% OwnerSep 03 '26Sale7.1732,263231,3264,144,952Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.10% OwnerSep 01 '26Sale7.0629,088205,3614,202,346Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.10% OwnerSep 02 '26Sale7.1925,131180,6924,177,215Sep 03 07:21 PM
MPM BioVentures 2014, L.P.10% OwnerSep 03 '26Sale7.1732,263231,3264,144,952Sep 03 07:21 PM
MPM BioVentures 2014, L.P.10% OwnerSep 01 '26Sale7.0629,088205,3614,202,346Sep 03 07:21 PM
MPM BioVentures 2014, L.P.10% OwnerSep 02 '26Sale7.1925,131180,6924,177,215Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.10% OwnerAug 31 '26Sale6.9944,259309,3704,231,434Aug 31 06:26 PM
MPM BIOVENTURES 2018, L.P.10% OwnerAug 27 '26Sale7.2038,922280,2384,279,426Aug 31 06:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200
  • Entrada Therapeutics Reports Third Quarter 2026 Financial Results (GlobeNewswire) -10.08%
  • Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer (GlobeNewswire) -6.81%
  • Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study (GlobeNewswire) -6.38%
  • Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 (GlobeNewswire)
  • Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program (GlobeNewswire) -9.70%
  • Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Entrada Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study (GlobeNewswire)
  • Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Entradas stock drops as DMD drugs efficacy falls short (Clinical Trials Arena)
  • Entrada shares dive as Duchenne results disappoint (BioPharma Dive) -57.27%
  • Entrada Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire)
  • Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study (GlobeNewswire)
  • Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.940-1.014-0.9400.912.307
2026Q22026-08-05-1.010-1.049-1.0130.902.238
2026Q12026-05-07-0.950-1.037-0.9490.882.928
2025Q42026-02-26-0.940-1.150-0.9411.307.417
2025Q32025-11-06-1.060-0.940-1.0641.618.625
2025Q22025-08-06-1.040-0.847-1.0431.979.654
2025Q12025-05-08-0.420-0.789-0.42220.5610.175
2024Q42025-02-270.030-0.6700.02637.4013.126
2024Q32024-11-05-0.350-0.728-0.34519.5812.325
2024Q22024-08-131.5500.3611.55094.7051.865
2024Q12024-05-070.680-0.5940.67559.1114.985
2023Q42024-03-13-0.290-0.168-0.28641.8423.695
2023Q32023-11-071.020-0.7351.02043.749.604
2023Q22023-08-08-0.780-0.690-0.78218.189.784
2023Q12023-05-10-0.210-0.651-0.20625.267.003
2022Q42023-03-06-0.790-0.827-0.7860.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-8.160-8.055-1.6380.000.00
2022FY-3.020-3.063-3.0240.000.00
2023FY-0.200-0.088-0.202129.01110.88
2024FY1.6801.0531.683210.79186.52
2025FY-3.470-3.606-3.47025.3630.45
2026FY--3.866--7.30
2027FY--3.538--18.02
2028FY--3.251--21.64
2029FY--2.795--72.77
2030FY--1.576--170.82

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-057103.120.0010.00
2026Q4S2026-10-297002.990.0010.00
2026Q4S2026-10-218006.950.0034.73
2026Q4S2026-10-198106.950.0034.73
2026Q4S2026-08-078216.950.0034.73
2026Q4S2026-08-058116.250.0029.13
2026Q4S2026-07-228009.250.0029.13
2026Q4S2026-07-218109.250.0029.13
2026Q4S2026-05-088129.250.0029.13
2026Q4S2026-05-078027.480.0024.00
2026Q4S2026-03-318018.290.0025.00
2026Q4S2026-03-307019.480.0025.00
2026Q4S2026-02-267019.480.0025.00
2026Q4S2026-02-096008.580.0025.00

Estimate history

EPS, annual-0.163-0.849-1.638-3.024-0.2021.683-3.475-3.8414
Period2019202020212022202320242025TTM
EPS, quarterly-0.3450.026-0.422-1.043-1.064-0.941-0.949-1.013-0.938
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000129.013210.78225.4213.98
Period2019202020212022202320242025TTM
Sales, quarterly19.5737.39820.5581.951.6141.2990.8750.8980.905
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual31.24931.24931.22431.39533.43737.57538.28439.15
Period2019202020212022202320242025MRQ
Shares, quarterly37.437.57537.94238.03438.21938.28438.82138.93739.15
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue3.9825.42210.78129.010.000.000.000.00
Cost of Goods Sold Incl. D&A3.194.103.772.841.901.120.330.10
Gross Profit0.7921.32207.01126.17-1.90-1.12-0.33-0.10
Selling, General and Administrative Excl. Other171.95177.32160.00129.3395.3550.0126.3411.72
Research and Development131.56136.47121.5397.0466.6135.9321.108.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-171.16-156.0047.01-3.16-97.25-51.13-26.67-11.82
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.001.900.000.000.000.000.00-6.27
Net Income Before Taxes-161.19-142.8366.4812.06-94.62-51.16-26.52-5.10
Income Taxes0.190.920.8618.740.000.000.000.00
Consolidated Net Income-161.39-143.7565.63-6.68-94.62-51.16-26.52-5.10
Net Income From Continuing Operations-161.39-143.7565.63-6.68-94.62-51.16-26.52-5.10
Net Income-161.39-143.7565.63-6.68-94.62-51.16-26.52-5.10
EPS (Recurring)-3.81-3.441.68-0.20-3.02-1.64-0.85-0.30
EPS (Basic, Before Extraordinaries)-3.84-3.471.76-0.20-3.02-1.64-0.85-0.16
EPS (Diluted)-3.84-3.471.68-0.20-3.02-1.64-0.85-0.16
EBITDA-167.97-151.9050.78-0.32-95.35-50.01-26.34-11.72
Non-Operating Income (Expense)9.9715.0719.4715.222.63-0.030.140.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.0315.4914.1510.369.892.530.330.29
Price To Earnings Ratio--10.85-----
Price To Sales Ratio67.6616.733.203.87----
Gross Margin19.7683.8998.2197.80----
Operating Margin-4,303.82-613.6622.30-2.45----
Net Margin-4,057.98-565.4831.13-5.18----
Shares Outstanding39.1538.2837.5733.4431.3931.2231.2531.25
Market Capitalization205.54205.54646.99503.10423.52484.71520.10-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.910.900.881.301.611.9520.5637.40
Cost of Goods Sold Incl. D&A0.700.800.810.891.201.100.950.99
Gross Profit0.200.100.070.410.410.8519.6136.41
Selling, General and Administrative Excl. Other41.8945.0642.3742.6247.4745.8041.4042.27
Research and Development31.6734.5732.2533.0737.1635.0831.1332.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-41.69-44.96-42.30-42.21-47.05-44.95-21.79-5.87
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.00-1.900.000.00
Net Income Before Taxes-39.72-42.73-39.68-39.07-43.48-42.92-17.35-0.74
Income Taxes0.030.040.040.090.650.180.00-1.87
Consolidated Net Income-39.74-42.76-39.72-39.16-44.13-43.10-17.351.13
Net Income From Continuing Operations-39.74-42.76-39.72-39.16-44.13-43.10-17.351.13
Net Income-39.74-42.76-39.72-39.16-44.13-43.10-17.351.13
EPS (Recurring)-0.94-1.01-0.95-0.94-1.06-1.01-0.420.03
EPS (Basic, Before Extraordinaries)-0.94-1.01-0.95-0.94-1.06-1.04-0.420.03
EPS (Diluted)-0.94-1.01-0.95-0.94-1.06-1.04-0.420.03
EBITDA-40.99-44.16-41.50-41.32-45.85-43.85-20.84-4.88
Non-Operating Income (Expense)1.972.232.623.143.573.924.445.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.774.073.753.444.043.994.023.71
Price To Earnings Ratio-----8.314.7410.85
Price To Sales Ratio67.6666.3192.0116.823.913.502.163.53
Gross Margin22.6510.918.0031.7925.6543.5995.4097.35
Operating Margin-4,606.52-5,007.02-4,834.63-3,249.27-2,915.18-2,305.08-105.99-15.69
Net Margin-4,391.38-4,762.03-4,539.09-3,014.93-2,734.45-2,210.41-84.393.02
Shares Outstanding39.1538.9438.8238.2838.2238.0337.9437.57
Market Capitalization205.54285.72483.15392.89220.62255.05339.86646.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments296.36420.00351.97188.71291.0639.0516.84
Short Term Receivables2.585.487.580.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets7.3214.5610.2221.167.640.900.59
Total Current Assets306.25440.04369.77209.88298.7039.9517.44
Net Property, Plant & Equipment67.7682.0592.6833.026.263.040.80
Total Investments and Advances3.293.953.953.950.000.000.00
Intangible Assets------0.00
Other Assets0.070.282.795.210.870.540.00
Total Assets377.38526.32469.19252.06305.8343.5318.24
Short Term Debt Incl. Current Port. of LT Debt4.147.567.918.410.000.000.00
Accounts Payable2.294.263.285.990.711.600.71
Income Tax Payable0.000.674.02----
Other Current Liabilities18.0227.00143.597.586.011.761.21
Total Current Liabilities24.4539.48158.8021.976.723.361.92
Long Term Debt46.7951.6560.3217.530.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.006.517.710.000.400.000.02
Total Liabilities71.2597.64226.8339.507.123.361.94
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0081.6631.82
Common Equity306.13428.68242.36212.55298.72-41.49-15.52
Total Shareholders Equity306.13428.68242.36212.55298.7240.1716.30
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity306.13428.68242.36212.55298.7240.1716.30
Total Liabilities & Stockholders Equity377.38526.32469.19252.06305.8343.5318.24
Book Value Per Share8.0011.417.256.779.57-1.33-0.50
Tangible Book Value Per Share8.0011.417.256.779.57-1.33-0.50
Full-Time Employees152183159130114--
Price to Book Ratio1.041.532.041.821.79-7.90-
Return on Assets-31.8113.18-1.85-33.92-29.29-85.88-
Return on Equity-39.1319.56-2.94-37.01-30.19-93.94-
Return on Invested Capital-40.7313.66-2.21-41.12-17.13-66.03-31.29
Quick Ratio12.5311.152.339.5544.4611.899.08
Current Ratio12.5311.152.339.5544.4611.899.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-161.39-143.7565.63-6.68-94.62-51.16-26.52-5.10
Depreciation3.204.103.772.841.901.120.330.10
Other Funds (Non Cash)17.1415.947.907.3310.052.600.34-5.98
Funds from Operations-141.04-123.7277.303.49-82.67-47.44-25.85-10.97
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital4.72-4.80-118.85136.31-11.11-3.420.280.17
Income Taxes Payable-0.62-0.67-3.364.02----
Cash from Operating Activities-136.32-128.51-41.56139.80-93.79-50.86-25.57-10.80
Capital Expenditures-0.01-1.04-3.16-5.61-2.89-4.58-2.33-0.63
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.010.00
Purchase or Sale of Investments153.99117.85-24.64-132.78-145.760.000.000.00
Purchase of Investments-42.14-141.61-437.72-407.21-221.980.000.000.00
Sale Or Maturity of Investments196.12259.46413.08274.4376.210.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities153.98116.81-27.80-138.40-148.65-4.58-2.32-0.63
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.640.89102.9621.040.48307.4650.090.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.640.89102.9621.040.48307.4650.090.04
Proceedsfrom Stock Options0.470.46100.1819.850.28306.5249.840.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.640.89102.9621.040.48307.4650.090.04
Net Change in Cash18.29-10.8233.6122.45-241.96252.0222.20-11.39
Free Cash Flow-136.33-129.55-44.72134.19-96.67-55.44-27.89-11.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow---3.72----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments193.01223.00254.86296.36326.84354.01
Short Term Receivables1.641.722.292.583.203.38
Inventories0.000.000.000.000.000.00
Other Current Assets8.307.989.737.328.2211.75
Total Current Assets202.95232.70266.87306.25338.26369.15
Net Property, Plant & Equipment60.5162.7665.2667.7670.5375.49
Total Investments and Advances3.293.293.293.293.953.95
Other Assets0.120.120.090.070.160.20
Total Assets266.88298.88335.52377.38412.90448.78
Short Term Debt Incl. Current Port. of LT Debt4.624.454.284.144.355.46
Accounts Payable4.873.752.932.293.171.86
Income Tax Payable---0.000.620.00
Other Current Liabilities16.3813.1811.9818.0215.8812.48
Total Current Liabilities25.8621.3719.2024.4524.0219.80
Long Term Debt42.6944.0945.4746.7948.0549.28
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.110.19
Total Liabilities68.5665.4764.6671.2572.1869.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity198.32233.41270.85306.13340.72379.50
Total Shareholders Equity198.32233.41270.85306.13340.72379.50
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity198.32233.41270.85306.13340.72379.50
Total Liabilities & Stockholders Equity266.88298.88335.52377.38412.90448.78
Book Value Per Share5.075.996.988.008.919.98
Tangible Book Value Per Share5.075.996.988.008.919.98
Full-Time Employees---152--
Price to Book Ratio1.041.051.581.150.580.61
Return on Assets-47.48-44.35-40.42-31.81-21.39-14.23
Return on Equity-59.88-54.09-48.28-39.13-27.11-18.12
Return on Invested Capital-16.49-15.41-12.56-11.10-11.35-10.05
Quick Ratio7.8510.8913.9012.5314.0818.64
Current Ratio7.8510.8913.9012.5314.0818.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-39.74-42.76-39.72-39.16-44.13-43.10
Depreciation0.670.840.810.891.231.03
Other Funds (Non Cash)4.524.704.203.734.384.09
Funds from Operations-34.55-37.22-34.72-34.55-38.53-37.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.594.76-6.982.3510.218.49
Income Taxes Payable0.000.000.00-0.620.62-0.80
Cash from Operating Activities-29.96-32.46-41.70-32.20-28.31-29.49
Capital Expenditures-0.16-0.01-0.040.210.17-0.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments43.0854.9627.0328.9148.9434.07
Purchase of Investments-7.92-3.92-11.82-18.47-26.57-16.55
Sale Or Maturity of Investments51.0058.8838.8647.3875.5050.63
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities42.9254.9526.9929.1249.1133.80
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.350.100.190.010.34
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.350.100.190.010.34
Proceedsfrom Stock Options0.000.320.000.140.000.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.350.100.190.010.34
Net Change in Cash12.9622.84-14.61-2.8920.804.64
Free Cash Flow-30.12-32.47-41.74-32.00-28.14-29.76

Revenue breakdown

Collaboration Service2024: 15.80M 2025: 5.20M
Consolidation, Policy2024: 982.00K 2025: -79.00K
Deferred Revenue At Inception2024: 123.50M
Recognition of Upfront and Milestone Payments2024: 70.50M 2025: 20.30M
United States2024: 210.78M 2025: 25.42M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.68%2.8M24.0M344.30K
2026-10-1513.68%3.3M23.9M360.80K
2026-09-3012.50%3.0M23.9M356.48K
2026-09-1511.48%2.7M23.9M365.97K
2026-08-319.92%2.3M23.7M347.59K
2026-08-148.78%2.4M27.0M375.31K
2026-07-319.57%2.1M22.4M480.10K
2026-07-1510.04%2.2M22.2M423.79K
2026-06-309.51%2.1M22.2M388.86K
2026-06-158.61%1.9M22.2M358.47K
2026-05-297.86%1.7M22.0M364.72K
2026-05-156.86%1.5M22.0M335.03K
2026-04-304.59%1.0M21.8M197.61K
2026-04-153.97%0.9M21.5M215.27K
2026-03-314.14%0.9M21.6M226.15K
2026-03-134.28%0.9M21.6M222.05K
2026-02-273.81%0.8M21.6M207.71K
2026-02-134.21%0.9M21.6M226.58K
2026-01-304.12%0.9M21.7M243.66K
2026-01-153.95%0.9M21.7M227.31K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.504.900.0018.5070.000.000.963-0.0130.001
call5.000.004.900.9020.9231.001.000.990-0.0390.000
call7.500.000.500.6523.32533.000.000.965-0.0780.001
call10.000.004.900.304.4901.000.000.293-0.0730.003
call12.500.004.900.005.2260.000.000.267-0.0810.003
put2.500.000.050.050.0001000.00-0.029-0.0640.001
put5.000.004.900.0030.3440.000.00-0.010-0.0380.000
put7.500.504.900.0010.5990.000.00-0.650-0.0570.003
put10.002.507.000.0010.3930.000.00-0.707-0.0710.003
put12.505.109.500.0011.2230.000.00-0.733-0.0810.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-09-10SCHEDULE 13D/ASEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-10144/ASEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09005.05M12
2026-08003.67M17
2026-07001.61M4
2026-060000
2026-0529.32K1628.76K2
2026-040032.38K1
2026-0300508.04K5
2026-020000
2026-010000
2025-120000
2025-111.61M43.61M3

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP13.07%
5AM Venture Management, LLC10.45%
BlackRock, Inc.6.65%
Merck & Co., Inc.4.48%
VANGUARD CAPITAL MANAGEMENT LLC3.27%
MPM BioImpact LLC3.23%
TCG Crossover Management, LLC2.73%
WELLINGTON MANAGEMENT GROUP LLP2.46%
MILLENNIUM MANAGEMENT LLC1.97%
StepStone Group LP1.96%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.46%
iShares Russell 2000 ETF1.98%
Fidelity Small Cap Index Fund0.83%
T. Rowe Price Health Sciences Fund, Inc.0.76%
VANGUARD EXTENDED MARKET INDEX FUND0.73%
iShares Russell 2000 Value ETF0.70%
JPMorgan U.S. Small Company Fund0.45%
VANGUARD RUSSELL 2000 INDEX FUND0.43%
iShares Biotechnology ETF0.39%
Fidelity Extended Market Index Fund0.32%

OakChart. TRDA. Cached 15 minutes.